• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Boundless Bio Inc.

    4/29/25 4:05:02 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BOLD alert in real time by email
    DEFA14A 1 bold_defa14a_2025.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.  )

     

    Filed by the Registrant☒

    Filed by a Party other than the Registrant☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    BOUNDLESS BIO, INC.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     


     

     

    img60772984_0.jpg

    LOGO BOUNDLESS BIO C/O TABULATOR P.O. BOX 8016, CARY, NC 27512-9903 Your vote matters! Boundless Bio, Inc. Annual Meeting of Stockholders Monday, June 23, 2025 8:00 AM Pacific Time Annual meeting will be held via live webcast. Please visit www.proxydocs.com/BOLD for more details. You may register to attend the meeting online and/or participate at www.proxydocs.com/BOLD. For a convenient way to view proxy materials, VOTE and obtain instructions to attend the meeting go to www.proxydocs.com/BOLD. To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before June 13, 2025. SEE REVERSE FOR FULL AGENDA Meeting Materials: Notice of Annual Meeting of Stockholders, Proxy Statement and Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be held on June 23, 2025 for stockholders of record as of April 25, 2025 To order paper materials, use one of the following methods. Internet: www.investorelections.com/BOLDCall: 1-866-648-8133 Email: [email protected] * If requesting materials by e-mail, please send a blank e-mail with the 12 digit control number located below in the subject line. No other requests, instructions or other inquiries should be included with your e-mail requesting materials. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved

     


     

     

    img60772984_1.jpg

    LOGO BOUNDLESS BIO Boundless Bio, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR EACH NOMINEE IDENTIFIED BELOW AND FOR PROPOSAL 2 PROPOSAL 1. Election of Directors 1.01 Christine Brennan, Ph.D. 1.02 Nancy Whiting, Pharm.D. 2. Ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. NOTE: Transact other business that may properly come before the meeting or any adjournment or postponement thereof.

     


    Get the next $BOLD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BOLD

    DatePrice TargetRatingAnalyst
    6/2/2025$5.00Buy
    H.C. Wainwright
    5/28/2025$3.00Outperform → Market Perform
    Leerink Partners
    12/13/2024Buy → Neutral
    Guggenheim
    More analyst ratings

    $BOLD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights

    BBI-355 and BBI-825 combination arm of the POTENTIATE trial is now open for enrollment BBI-940 is on track for submission of an investigational new drug application in the first half of 2026 $127 million in cash supports operations into the first half of 2028, throughexpected proof-of-concept clinical readouts for both programs SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) --  Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fisc

    8/5/25 7:00:00 AM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board

    HOUSTON, July 31, 2025 /PRNewswire/ -- The Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of Rice University's health and medical technology discoveries into cures, announced today the appointment of Carolyn Ng to its external advisory board. A current business unit partner at TPG Life Sciences Innovations, Ng brings expertise in biotech and company building with a track record of guiding early to midstage companies across a wide range of therapeutic areas. "Carolyn's deep understanding of translational science, combined with her passion for fostering high-impact ventures, makes her an ideal addition to the board," said Omid Veiseh, professor of b

    7/31/25 7:00:00 AM ET
    $BCAX
    $BCYC
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

    SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that   Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference. The fireside chat session is scheduled for Monday, June 9, in Miami, FL, at 9:20 a.m. ET. A live and archived webcast of the session will be accessible under "Events & Presentations" in the Investors section of Boundless Bio's website. About Boundless

    6/5/25 4:58:28 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Brennan Christine

    4 - Boundless Bio, Inc. (0001782303) (Issuer)

    6/23/25 5:21:20 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Christensen James

    4 - Boundless Bio, Inc. (0001782303) (Issuer)

    6/23/25 5:16:53 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Lew Jennifer

    4 - Boundless Bio, Inc. (0001782303) (Issuer)

    6/23/25 5:15:17 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLD
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Boundless Bio Inc.

    SCHEDULE 13G/A - Boundless Bio, Inc. (0001782303) (Subject)

    8/14/25 5:57:29 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Boundless Bio Inc.

    10-Q - Boundless Bio, Inc. (0001782303) (Filer)

    8/5/25 7:10:20 AM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boundless Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Boundless Bio, Inc. (0001782303) (Filer)

    8/5/25 7:05:28 AM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Boundless Bio with a new price target

    H.C. Wainwright initiated coverage of Boundless Bio with a rating of Buy and set a new price target of $5.00

    6/2/25 8:50:41 AM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boundless Bio downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Boundless Bio from Outperform to Market Perform and set a new price target of $3.00

    5/28/25 8:09:07 AM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boundless Bio downgraded by Guggenheim

    Guggenheim downgraded Boundless Bio from Buy to Neutral

    12/13/24 7:26:11 AM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLD
    Leadership Updates

    Live Leadership Updates

    View All

    Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board

    HOUSTON, July 31, 2025 /PRNewswire/ -- The Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of Rice University's health and medical technology discoveries into cures, announced today the appointment of Carolyn Ng to its external advisory board. A current business unit partner at TPG Life Sciences Innovations, Ng brings expertise in biotech and company building with a track record of guiding early to midstage companies across a wide range of therapeutic areas. "Carolyn's deep understanding of translational science, combined with her passion for fostering high-impact ventures, makes her an ideal addition to the board," said Omid Veiseh, professor of b

    7/31/25 7:00:00 AM ET
    $BCAX
    $BCYC
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer

    SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Robert ("Bob") Doebele, M.D., Ph.D., has been appointed as Chief Medical Officer. "We are excited to have Bob join Boundless at this pivotal time as we continue to advance the BBI-355 Phase 1/2 POTENTIATE trial and approach the selection of a development candidate for our Kinesin program," said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. "Bob has been a driving force behind precisio

    2/3/25 10:00:00 AM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLD
    Financials

    Live finance-specific insights

    View All

    Boundless Bio Announces Portfolio Prioritization and Runway Extension

    Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first half of 2028, through expected proof-of-concept clinical readouts for each program Conference call and webcast to be held Tuesday, May 27 at 8:00 am ET SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today provided business updates focused on optimizing the Company's portfolio for p

    5/23/25 4:01:00 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Boundless Bio Inc.

    SC 13D - Boundless Bio, Inc. (0001782303) (Subject)

    10/29/24 6:32:08 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care